Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Selector® 6.0, the latest version of its innovative enterprise software solution for automation of next generation sequencing (NGS)-based workflows. The software has been developed in collaboration with biopharma customers and is rapidly being adopted by leading biopharma companies to increase efficiencies, from research to development and into biosafety testing.
Efficient NGS analysis and comprehensive data management throughout an organization are required to address increasing numbers of projects and to speed up the development of biotherapeutics. Genedata Selector automates NGS-based workflows with wizard-style playbooks that guide users through the entire workflow from sample registration to report generation. These playbooks can be adapted to any laboratory’s workflows; using pre-approved data processing pipelines, they enable scientists to perform routine analysis in cell line development and adventitious agent detection independent of expert bioinformatics support. Scientists can access results immediately, resulting in significant time savings.
Genedata Selector 6.0 Highlights
The newest release of Genedata Selector includes NGS data processing workflows which can be approved and locked for use in playbooks to minimize the risk of variations in data processing. This automation streamlines and standardizes routine data processing and allows scientists to focus more on their experiments and interpretation of the data. New features to enhance the user experience include a configurable dashboard with status cards to provide scientists and managers quick access to project status and other information. A new, robust genome loading tool enhances the system performance and simplifies genome database maintenance. In Genedata Selector 6.0, sample and data management, visualization, and analysis are tightly integrated to allow for full data transparency and to enable audit reports with time-stamped transactions.
The playbooks allow complex NGS analysis in cell line development and process optimization, such as clone selection with Targeted Locus Amplification (TLA), to be brought in-house and drastically reduce the time required to generate results. In addition, playbooks for adventitious agent detection enable rapid on-site biosafety analysis of cell banks, raw material, and lot release testing, saving weeks compared to sending samples out for analysis to a CRO.
”With Genedata Selector we focus on streamlining and automating complex NGS-based applications for the biopharmaceutical industry, to accelerate the digitalization of our rapidly growing customer base,” said Dr. Othmar Pfannes, Ph.D., CEO of Genedata. “Biopharmas that choose to manage innovation on Genedata Selector 6.0 can take a big leap forward to reach full digitalization today and enable easy access to high quality data within their organizations.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.